Zydus Lifesciences Expands Portfolio with ₹84 Crore Acquisition of Sterling Biotech’s API Business

Zydus Lifesciences has made a significant move in the pharmaceutical industry by approving the acquisition of Sterling Biotech's Active Pharmaceutical Ingredients (API) business for ₹84 crore. This announcement comes on the heels of Zydus's previous decision to acquire a 50% stake in Sterling Biotech, further consolidating its position in the market.

The Acquisition Details

On September 17, 2024, Zydus Lifesciences' board of directors approved a Business Transfer Agreement (BTA) to acquire the API business of Sterling Biotech on a slump sale basis. This means the acquisition will occur without assigning values to individual assets or liabilities, based on a pre-defined lump-sum consideration of ₹84 crore (₹840 million). This strategic acquisition is part of Zydus Lifesciences’ broader strategy to enhance its product portfolio and expand its market presence.

Sterling Biotech is a prominent manufacturer known for its extensive range of pharmaceutical products. The company produces pharmaceutical gelatin, di-calcium phosphate (DCP), and APIs including lovastatin, doxorubicin, epirubicin, and daunorubicin. These products are critical components in various therapeutic areas, making this acquisition a strategic fit for Zydus Lifesciences.

Strategic Fit and Business Synergies

The API business of Sterling Biotech is particularly valuable to Zydus Lifesciences due to its fermentation-based products portfolio. Sterling Biotech’s manufacturing facility located in Masar, Gujarat, is in close proximity to Zydus’s existing facility at Dabhasa. This geographical advantage allows for streamlined operations and potential cost efficiencies, aligning with Zydus Lifesciences' strategic and commercial objectives.

Zydus Lifesciences has emphasized that the acquisition is a strategic fit, enhancing its capability in the API segment. The integration of Sterling Biotech’s API business will not only expand Zydus’s product offerings but also enhance its operational capabilities in the pharmaceutical sector.

Recent Developments and Acquisitions

Prior to this acquisition, Zydus Lifesciences had already expanded its stake in Sterling Biotech by acquiring a 50% share from the existing owner, Perfect Day, for ₹550 crore. This earlier move was part of Zydus’s strategy to strengthen its foothold in the pharmaceutical industry and diversify its product range.

Sterling Biotech has been a significant player in the pharmaceutical market, with a robust portfolio of products and a solid manufacturing base. The acquisition of Sterling Biotech’s API business represents a key milestone for Zydus Lifesciences, marking a substantial step forward in its growth strategy.

Market Reaction and Future Outlook

The announcement of the acquisition initially led to some selling pressure on Zydus Lifesciences’ shares during the trading session on September 17, 2024. However, the long-term outlook remains positive, as the integration of Sterling Biotech’s API business is expected to bring substantial benefits to Zydus Lifesciences.

The acquisition aligns with Zydus Lifesciences' strategy of expanding its capabilities and enhancing its product portfolio in the pharmaceutical sector. By integrating Sterling Biotech’s API business, Zydus is well-positioned to leverage synergies and drive growth in its pharmaceutical operations.

Industry Context and Implications

Sterling Biotech’s API business includes a range of important pharmaceutical ingredients, which are crucial for various therapeutic applications. The addition of these products to Zydus Lifesciences' portfolio will enhance its capabilities in the API segment and provide a competitive edge in the market.

The pharmaceutical industry is witnessing increased consolidation as companies seek to expand their product offerings and operational capabilities. Zydus Lifesciences' acquisition of Sterling Biotech's API business is a testament to this trend, highlighting the strategic importance of such transactions in achieving growth and enhancing market presence.

ALSO READ| Multi-Cap vs. Flexi-Cap Mutual Funds: Which Is Better for Investment in the Current Market?

Zydus Lifesciences' acquisition of Sterling Biotech’s API business for ₹84 crore is a strategic move aimed at strengthening its position in the pharmaceutical industry. The integration of Sterling Biotech’s API segment will enhance Zydus’s product portfolio and operational capabilities, aligning with its long-term growth objectives. As the pharmaceutical market continues to evolve, such strategic acquisitions play a crucial role in expanding capabilities and driving industry growth.

Source: MoneyControl